Key facts and Forecast

Results of Q1 2022

  • Group sales increase by 12.2% to € 5.2 billion; EBITDA pre up 7.8% to € 1.6 billion; EBITDA pre margin 31.3%
  • Growth story continues to materialize
  • High margins in all three businesses despite challenging economic headwinds and increasing global uncertainty

Forecast for fiscal 2022

  • Company specifies forecast for net sales, EBITDA pre and earnings per share pre
  • Net sales between € 21.6 billion and € 22.8 billion; EBITDA pre in a range between € 6.6 billion and € 7.1 billion; earnings per share pre between € 9.60 and € 10.50

Overview: Business performance in Q1 2022

       

Group net sales:

€ 5.2 bn.

+12.2%

(organic: +7.8%)

EBITDA pre:

€ 1.6 bn.

+7.8%

(organic: +1.6%)

Life Science:

€ 2.4 bn.

+14.7%

(organic: +9.7%)

Healthcare:

€ 1.8 bn.

+9.5%

(organic: +6.5%)

Electronics:

€ 957 m.

+11.2%

(organic: +5.2%)

We have made a promising start to 2022, with our Big 3 generating strong growth and attractive margins.

Belén Garijo

Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

Annual Reports Archive

Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more

Related News

View All News
  1. Press Releases

    Merck KGaA, Darmstadt, Germany, Delivers Strong First Quarter

    Merck KGaA, Darmstadt, Germany, achieved strong results in the first quarter of 2022. Net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter.

    2022/05/12

Upcoming Events

View All Events

Gangolf Schrimpf

Financial Communications

Constantin Fest

Head of Investor Relations

+49 6151 72-5271

+49 6151 72 91-5271

Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.

Check Share Price